November 10-11: Conference
Complex Generic Drugs are a large and diverse group of products with complex active ingredients or formulations, complex routes of delivery (such as locally acting drugs in dermatological products and complex ophthalmological products), or complex dosage forms (e.g., transdermals or extended release injectables). They also include complex drug-device combination products (such as auto injectors and metered dose inhalers) and other products where complexity or uncertainty concerning the approval pathway or possible alternative development approaches would benefit from early scientific engagement
Though the products in this diverse collection provide important therapies to patients, their complex elements make them difficult to produce, thus impeding access to the more affordable generic versions of these life-saving medicines.
The DIA’s Complex Generics Conference will examine current knowledge and ongoing scientific research where industry, regulators, and stakeholders dialog on today’s best answers and solutions to key questions regarding the development of complex generic drug-device combination products.
While we work on the agenda for 2022, please view our 2020 Final Program to see the topics presented.
Social distancing measures may be in place at the time of the event. Therefore, we encourage you to register and make your housing arrangements early due to potential limited capacity. Don’t miss out on your chance to meet live again with your friends and colleagues!
Who should attend?
- Biopharmaceutical, Device, and Combination Product R&D and Development
- Generics Development
- Clinical Research
- Regulatory Affairs
- Quality Assurance and Control
- Consulting, Legal, Government Affairs
Rosario LoBrutto, PhD • Executive Director, Head of Scientific Affairs
Sandoz, United States
James Wabby, MHS • Global Head, Regulatory Affairs, Emerging Technologies and Combination Products
AbbVie, Inc., United States
Roisin Wallace • Vice President, Head of Global Device Development
Quanying Bao • Assistant Research Professor
University of Connecticut, United States
Brandon Wood • Associate Director, Regulatory Affairs
Teva Pharmaceuticals USA, Inc., United States
Sivakumar R Vaithiyalingam, PhD • Principal
ARK Pharma Services LLC, United States
Representative Invited • DIA, United States